← Back to all trials
Not Yet Recruiting
NCT07806552
Middle Meningeal Artery Embolization in Patients With Chronic Subdural Hematoma
Conditions: Middle Meningeal Artery Embolization, Chronic Subdural Hematomas
Sex: All
Healthy volunteers: No
Phase: NA
Enrollment: 35
Sponsor: Assiut University
Summary
Primary : to evaluate the efficacy of MMAE on resolution and recurrence of hematoma in patients with CSDH.
Secondary : evaluate the effect of MMAE on functional outcome, radiological changes, the need to repeat surgery, duration of hospital stay, time for hematoma to resolve.
Eligibility Criteria
Inclusion Criteria:
1. Any age.
2. Radiologically confirmed chronic subdural hematoma (CSDH) on CT or MRI either Unilateral or Bilateral CSDH.
3. Patients considered suitable for standard surgical treatment of CSDH.
4. First presentation or recurrent CSDH requiring treatment.
Exclusion Criteria:
1. Acute subdural hematoma or acute-on-chronic SDH where the acute component is the primary pathology.
2. Acute and severe neurological deterioration.
3. Subdural hematomas secondary to:
* Intracranial tumors.
* Intracranial infections.
4. Contraindications to angiography or embolization (for the MMAE group), such as:
* Severe contrast allergy.
* Untreatable coagulopathy.
* Severe renal failure precluding contrast administration
5. Severe tortuosity or anatomical variations of the external carotid artery/MMA making catheterization unfeasible.
Source: ClinicalTrials.gov (NCT07806552). StuddyBuddy aggregates publicly available trial information.
